This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Reasons to Retain West Pharmaceutical (WST) in Your Portfolio
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Quest Diagnostics (DGX) Advances Transplant Testing Service
by Zacks Equity Research
These services by Quest Diagnostics (DGX) are available to recipients and living donors across the United States (excluding Alaska and Hawaii), broadening access for both donor and patient.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Neogen (NEOG) Receives New Label Claims for Viroxide Super
by Zacks Equity Research
Neogen's (NEOG) Viroxide Super active constituents are potassium peroxymonosulfate and sodium chloride, which have been verified effective against multiple industry-relevant bacteria and viruses.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Chemed (CHE) Up on Roto-Rooter Sales Growth, Strong Admissions
by Zacks Equity Research
Chemed (CHE) records increases in drain cleaning, plumbing, excavation and water restoration revenues within the Roto-Rooter branch commercial business.
Henry Schein (HSIC) Bolsters Dental Practices With AI Tools
by Zacks Equity Research
Henry Schein (HSIC) integrates AI-enabled solutions, Dentrix Ascend Detect AI and Dentrix Ascend Voice, into its cloud-based dental software.
Syneos Health's (SYNH) New Microsoft Deal to Expand AI Usage
by Zacks Equity Research
With the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft.
Merit Medical's (MMSI) New Launch to Boost its Product Suite
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly enhance patient outcomes.
NuVasive's (NUVA) Precice System Cleared for Pediatric Patients
by Zacks Equity Research
NuVasive (NUVA) receives FDA 510(k) clearance for using the Precice limb lengthening system for treating pediatric patients.
Universal Health (UHS) Up 26% in 6 Months: More Room to Run?
by Zacks Equity Research
Universal Health (UHS) is well-poised for growth on the back of improved patient volumes, acquisitions and robust cash-generating abilities.
Catalent (CTLT) Inks Deal for New & Effective Drug Delivery
by Zacks Equity Research
Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
BD's (BDX) New FDA Approval to Improve Vaginitis Testing
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of vaginitis.
Catalent's (CTLT) Tie-Up to Accelerate Clinical Trial Timelines
by Zacks Equity Research
Catalent's (CTLT) latest collaboration is expected to leverage multiple services that reduce drug development timelines.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Shockwave Medical (SWAV) Launches New IVL Catheter in U.S.
by Zacks Equity Research
Shockwave Medical's (SWAV) latest U.S. launch is expected to serve a wider patient pool.
Here's Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
PacBio's (PACB) Latest Offering to Enhance Genome Analysis
by Zacks Equity Research
PacBio's (PACB) new informatics analysis method, Paraphase, will enable researchers to genotype gene paralogs and pseudogenes with high accuracy.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a concern.
The Zacks Analyst Blog Highlights Ameriprise Financial, Everest Re Group, Microchip Technology, Henry Schein and HSBC Holdings
by Zacks Equity Research
Ameriprise Financial, Everest Re Group, Microchip Technology, Henry Schein and HSBC Holdings are part of the Zacks top Analyst Blog.
Henry Schein (HSIC) Aids Growth of Ambulatory Surgery Centers
by Zacks Equity Research
Henry Schein (HSIC) joined ASCA as part of its commitment to augment the value of ambulatory surgery centers.
OPKO Health (OPK) to Develop EBV Vaccine With Latest Tie-Up
by Zacks Equity Research
OPKO Health's (OPK) entry into a worldwide license and collaboration agreement with Merck is expected to aid in developing a vaccine against EBV.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.